<https://rdf.molmedb.upol.cz/reference/ref3115> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490090>,
		<https://rdf.molmedb.upol.cz/interaction/membrane46>,
		<https://identifiers.org/molmedb/MM489195>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.8b00650"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490092>,
		<https://rdf.molmedb.upol.cz/interaction/method71>;
	<http://purl.org/ontology/bibo/pmid> "29878763"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Londregan AT, Wei L, Xiao J, Lintner NG, Petersen D, Dullea RG, McClure KF, Bolt MW, Warmus JS, Coffey SB, Limberakis C, Genovino J, Thuma BA, Hesp KD, Aspnes GE, Reidich B, Salatto CT, Chabot JR, Cate JHD, Liras S, Piotrowski DW.: Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents. J Med Chem, Volume 61 (13), 2018"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1009591> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .
<https://rdf.molmedb.upol.cz/interaction/int1008070> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .
<https://rdf.molmedb.upol.cz/interaction/int1009594> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .
<https://rdf.molmedb.upol.cz/interaction/int1009592> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .
<https://rdf.molmedb.upol.cz/interaction/int1009595> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .
<https://rdf.molmedb.upol.cz/interaction/int1008071> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3115> .